Cathepsin G-mediated activation of pro-matrix metalloproteinase 9 at the tumor-bone interface promotes transforming growth factor-β signaling and bone destruction

Molecular Cancer Research

Volumn 7, Issue 8, 2009, Pages 1224-1233

  Wilson, Thomas J ^a   Nannuru, Kalyan C ^a   Singh, Rakesh K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN G; GELATINASE B; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE TUMOR; CELL ACTIVATION; CELL INTERACTION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STROMA CELL; UPREGULATION;

ANIMALS; BONE AND BONES; BONE NEOPLASMS; CATHEPSIN G; ENZYME ACTIVATION; ENZYME PRECURSORS; MAMMARY TUMOR VIRUS, MOUSE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; OLIGONUCLEOTIDES, ANTISENSE; OSTEOLYSIS; RANK LIGAND; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 69449105858     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0028     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-593
3. Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-κB ligand. Cancer Res 2008;68:5803-5811
4. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176 (Pubitemid 28180851)
5. Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 2006;25:541-549 (Pubitemid 46071863)
6. Kitazawa S, Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 2002;198:228-236 (Pubitemid 35243881)
7. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-1664
8. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-1244 (Pubitemid 32494540)
9. Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET. Soluble receptor activator of nuclear factor κB Fc diminishes prostate cancer progression in bone. Cancer Res 2003;63:7883-7890 (Pubitemid 37466723)
10. Wilson TJ, Singh RK. Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases. Biochim Biophys Acta Rev Cancer 2008;1785:85-95.
11. Futakuchi M, Nannuru K, Varney ML, et al. Transforming growth factor-β signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation. Cancer Sci 2009;100:71-81.
12. Yin JJ, Selander K, Chirgwin JM, et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103:197-206. (Pubitemid 29053137)
13. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 2000;14:163-176 (Pubitemid 30070982)
14. Olofsson A, Miyazono K, Kanzaki T, Colosetti P, Engstrom U, Heldin CH. Transforming growth factor-β1, -β2, and -β3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. J Biol Chem 1992;267:19482-19488
15. Koli K, Saharinen J, Hyytiainen M, Penttinen C, Keski-Oja J. Latency, activation, and binding proteins of TGF-β. Microsc Res Tech 2001;52:354-362 (Pubitemid 32167823)
16. Yoshinaga K, Obata H, Jurukovski V, et al. Perturbation of transforming growth factor (TGF)-β1 association with latent TGF-β binding protein yields inflammation and tumors. Proc Natl Acad Sci U S A 2008;105:18758-18763
17. Shamamian P, Schwartz JD, Pocock BJ , et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 2001;189:197-206. (Pubitemid 32946031)
18. Sundaram K, Nishimura R, Senn J, Youssef RF, London SD, Reddy SV. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res 2007;313:168-178 (Pubitemid 44958461)
19. Fujisaki K, Tanabe N, Suzuki N, et al. Receptor activator of NF-κB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Life Sci 2007;80: 1311-1318 (Pubitemid 46320458)
20. Nakao A, Imamura T, Souchelnytskyi S, et al. TGF-β receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J 1997;16:5353-5362
21. Lynch CC, Hikosaka A, Acuff HB, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005;7:485-496 (Pubitemid 40719131)
22. Tanaka S. [A novel therapeutic vaccine approach against RANKL that prevents pathological bone destruction]. Clin Calcium 2005;15:62-66
23. Gordon AH, O'Keefe RJ, Schwarz EM, Rosier RN, Puzas JE. Nuclear factor-κB-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone. Cancer Res 2005;65:3209-3217
24. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001;61:4432-4436 (Pubitemid 32685771)
25. Tezuka K, Nemoto K, Tezuka Y, et al. Identification of matrix metalloproteinase 9 in rabbit osteoclasts. J Biol Chem 1994;269:15006-15009 (Pubitemid 24198341)
26. Inui T, Ishibashi O, Origane Y, Fujimori K, Kokubo T, Nakajima M. Matrix metalloproteinases and lysosomal cysteine proteases in osteoclasts contribute to bone resorption through distinct modes of action. Biochem Biophys Res Commun 1999;258:173-178 (Pubitemid 29287022)
27. Okada Y, Naka K, Kawamura K, et al. Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase = gelatinase B) in osteoclasts: implications for bone resorption. Lab Invest 1995;72:311-322
28. Wucherpfennig AL, Li YP, Stetler-Stevenson WG, Rosenberg AE, Stashenko P. Expression of 92 kD type IV collagenase/gelatinase B in human osteoclasts. J Bone Miner Res 1994;9:549-556 (Pubitemid 24090338)
29. Reponen P, Sahlberg C, Munaut C, Thesleff I, Tryggvason K. High expression of 92-kDa type IV collagenase (gelatinase) in the osteoclast lineage during mouse development. Ann N Y Acad Sci 1994;732:472-475 (Pubitemid 24109410)
30. Massague J. TGF-β signal transduction. Annu Rev Biochem 1998;67:753-791
31. Heldin CH, Miyazono K, Ten DP. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-471 (Pubitemid 28013118)
32. Miyazono K, Ten DP, Heldin CH. TGF-β signaling by Smad proteins. Adv Immunol 2000;75:115-157
33. Lu Z, Murray JT, Luo W, et al. Transforming growth factor β activates Smad2 in the absence of receptor endocytosis. J Biol Chem 2002;277:29363-29368 (Pubitemid 41079219)
34. Bennett CF, Cowsert LM. Antisense oligonucleotides as a tool for gene functionalization and target validation. Biochim Biophys Acta 1999;1489:19-30.
35. Overall CM, Blobel CP. In search of partners: linking extracellular proteases to substrates. Nat Rev Mol Cell Biol 2007;8:245-257
36. Selak MA, Chignard M, Smith JB. Cathepsin G is a strong platelet agonist released by neutrophils. Biochem J 1988;251:293-299 (Pubitemid 18099385)